Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly Carfilzomib in Advanced Solid Tumors
NCT02257476Phase 1Completed
- Sponsor
- Emory University
- Start
- Aug 2014
- Primary completion
- Nov 2016
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in solid tumor, sponsored by Emory University. Primary endpoint: Maximum Tolerated Dose up to 18 months. Started Aug 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02257476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02257476.